AstraZeneca: Aspen Buys Remaining Rights to Anesthetic Portfolio
14 Septembre 2017 - 8:56AM
Dow Jones News
By Ian Walker
Pharmaceutical company AstraZeneca PLC (AZN.LN) said Thursday
that Aspen Group's (APZ.AU) unit will buy the remaining rights to
its anesthetic medicines for up to $766 million.
Following the initial deal entered into in June 2016--which saw
Aspen Global Incorporated gain exclusive commercialization rights
to the medicines in markets outside the U.S.--Aspen Global will now
buy the remaining rights to Diprivan, EMLA,
Xylocaine/Xylocard/Xyloproct, Marcaine, Naropin, Carbocaine and
Citanest.
It is paying an initial $555 million for the remaining rights to
the intellectual property and manufacturing knowledge related to
the anesthetic medicines, plus a further $211 million based on
performance.
AstraZeneca said it will continue to manufacture and supply the
medicines to Aspen Global during a transition period of up to five
years.
Write to Ian Walker at ian.walker@wsj.com; @IanWalk40289749
(END) Dow Jones Newswires
September 14, 2017 02:41 ET (06:41 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
Aspen (ASX:APZ)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Aspen (ASX:APZ)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Aspen Group (Australian Stock Exchange): 0 recent articles
Plus d'articles sur Aspen Stapled